S21-311 CCL5-mediated activation of immune adverse reaction in immune check point inhibitor-treated cancer patients An increasing number of cancer patients are now receiving immune checkpoint inhibitors (ICIs), which boost the immune system to attack cancer cells. Sean Wu Patricia Nguyen Han Zhu